Sanara MedTech (SMTI)

• Market cap: $294M
• 1 day: -4.59%
• 5 days: -5.63%
• 1 month: -0.91%
• 3 months: -9.73%
• 6 months: -0.80%
• Year to date: 1.78%
• 1 year: -10.28%
• 5 years: 19.60%
• 10 years: 19.60%
• Sector: Healthcare
• Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies

About: Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.

Employees: 108

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

800% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 1

380% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 5

28% more capital invested

Capital invested by funds: $24.6M [Q3] → $31.6M (+$7M) [Q4]

16% more funds holding

Funds holding: 44 [Q3] → 51 (+7) [Q4]

1.59% more ownership

Funds ownership: 9.31% [Q3] → 10.9% (+1.59%) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $44 31% upside
• Avg. target: $47 40% upside
• High target: $50 48% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Cantor Fitzgerald Ross Osborn 59% 1-year accuracy 27 / 46 met price target	31% upside $44	Overweight Reiterated	23 Jan 2025
HC Wainwright & Co. Yi Chen 42% 1-year accuracy 67 / 161 met price target	48% upside $50	Buy Reiterated	23 Jan 2025